Objectives. Detecting the prevalence of cardiovascular impairment and anemia in patients with predialysis G5 chronic kidney disease. Material and methods. Retrospective study included 61 patients in the Nephrology Department, Republican Clinical Hospital „Timofei Mosneaga” during 2022, with the diagnosis of CKD G5 predialysis. Results. The lot of patients included 15 men (24.59%), aged 4475 years, 46 women (75.49%), aged 33-79 years. Causes leading to CKD G5: Autosomal dominant polycystic kidney disease - 13 patients; DM type 2 - 11 patients; Chronic diffuse glomerulonephritis 17 patients; Hypertensive nephropathy - 8 patients; Chronic pyelonephritis - 12 patients. Hypertension was present in 55 patients (90.16%), 38 (69.09%) patients were resistant to treatment. 50 patients (81.95%) developed heart disease: hypertensive 34 (55.73%), dysmetabolic 19 (31.14%) and ischemic 5 (8.19%). In the group there were 3 patients (4.91%) with permanent tachysystolic atrial fibrillation and 4 patients (6.55%) with stable angina pectoris class II. Valvular involvement was detected in 30 patients (49.18%), the most common being mitral valve insufficiency in 14 patients (22.95%) and tricuspid valve insufficiency in 12 patients (19.67%). All patients developed HF, predominantly NYHA Class II AHA/ACC stage B- 46 patients (75.40%). Anemia was detected in 45 patients (73,74%), mild anemia was dominant 29 patients (64,44%). Conclusions. Patients with predialysis CKD G5 have frequent comorbidities and serious extrarenal complications, including damage of the cardiovascular system. These patients are more likely to develop hypertension, valvular damage leading to increased risk of mortality from cardiovascular causes.